Antitumor agents of a kind, and a histone deacetylase inhibitor is at least selected from the group consisting of antineoplastic agents which exhibit anti-tumor effect by forming crosslinks DNA, antimetabolite antitumor agent and a taxane antitumor agent anti-tumor agent to be in combination. In accordance with the present invention, side effects can be reduced, anti-tumor agents with antitumor activity superior is provided. None [Selection Figure]DNAに架橋を形成し抗腫瘍効果を示す抗腫瘍剤、代謝拮抗物質系抗腫瘍剤およびタキサン系抗腫瘍剤からなる群から選ばれる少なくとも一種の抗腫瘍剤と、ヒストンデアセチラーゼ阻害剤とを組み合わせてなる抗腫瘍剤。本発明によれば、副作用が軽減され、優れた抗腫瘍作用を有する抗腫瘍剤が提供される。【選択図】なし
